CD47 and neoplasm: Furthermore, whereas in a poorly immunogenic B16F10 syngeneic melanoma mouse model CD47 blocking did not synergise with the B16F10‐specific monoclonal antibody TA99 (anti‐TRP‐1), combination with PD‐L1 blocking did control tumour growth in vivo and triple combination with anti‐TRP‐1 cured a majority of mice (60%).83